Crossmark

Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice

Crossref DOI link: https://doi.org/10.1186/s12885-019-5354-5

Published Online: 2019-02-14

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Weycker, Derek https://orcid.org/0000-0002-5405-2215
Hatfield, Mark

Grossman, Aaron

Hanau, Ahuva

Lonshteyn, Alex

Sharma, Anjali

Chandler, David
Funding

Funding for this research was provided by:

Amgen
License Information

Text and Data Mining valid from 2019-02-14
More Information

Article History

Received: 14 November 2018

Accepted: 5 February 2019

First Online: 14 February 2019

Ethics approval and consent to participate

: The data extracts were de-identified prior to their release to study investigators, and thus their use for health services research is compliant with the HIPAA Privacy Rule and federal guidance on Public Welfare and the Protection of Human Subjects. This research is thus exempt from IRB review.

: Not applicable.

: Aaron Grossman, Ahuva Hanau, Alexander Lonshteyn, and Derek Weycker are employed by PAI. David Chandler, Mark Hatfield, and Anjali Sharma are employed by, and own stock in, Amgen Inc.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.